CFO Shantharam Harish bought 75,000 shares (75.0K) of ALXO at $0.78; stock -68.7% from 52-week high in unprofitable biotech.
Shantharam Harish, Chief Financial Officer, purchased 75,000 shares at $0.78 on 2025-08-18 for a total value of $58,402.50, establishing an initial position in the company. This purchase occurs in a severely distressed context: ALXO trades at $0.83, down 68.7% from its 52-week high of $2.65, while the company reported a net loss of $-25,949,000 against quarterly revenue of only $527,000.00. The stock has recovered +72.9% over the prior 30 days and +73.3% over 90 days, suggesting ALXO has experienced a sharp recent rally from depressed levels. A CFO's initial establishment of a material position (75,000 shares) in a capital-constrained, unprofitable oncology company warrants investor attention to the underlying clinical or strategic developments driving this transaction, and whether recent price recovery reflects genuine business momentum or sector-wide rebound.